New Leadership at EpiVax to Propel Technology Forward
EpiVax, Inc. has recently made significant strides in its technology sector by appointing Guilhem Richard as the new Chief Technology Officer. Dr. Richard has been a pivotal part of EpiVax's immunoinformatics team since 2014. He played an integral role in creating a sophisticated computational platform named Ancer that focuses on personalized cancer vaccines. His expertise was further utilized at EpiVax’s subsidiary, EpiVax Therapeutics, from 2019 to 2024, where he led transformative projects. Now, he embarks on a mission to innovate at EpiVax by directing the creation of advanced computational tools for assessing immunogenicity.
Advancements in Technology and Tools
The promotion of Dr. Richard aligns with EpiVax's commitment to technological advancements. The company has recently reported remarkable updates in its capabilities, particularly in leveraging AI and machine learning within its ISPRI platform. These enhancements are designed to improve assessments of immunogenicity risk for biologic therapeutics, thereby increasing the reliability of the predictive models physicists and biologists use. For instance, enhancements to the JanusMatrix model enable researchers at EpiVax to accurately predict tolerated epitopes, resulting in a notable 50% improvement in both precision and recall.
The Impact of New Immunogenicity Models
Furthermore, EpiVax has developed new immunogenicity models designed to predict anti-drug antibodies (ADA) against monoclonal therapies. These innovative models have achieved a remarkable six-fold accuracy against existing methods, while effectively cutting down false negatives by 85%. This fresh approach ensures that developers can have more confidence in their immunogenicity assessments, which is critical in the drug development lifecycle. The newly updated tools will soon be accessible via the ISPRI platform, set to be available on a SaaS and fee-for-service basis.
Regulatory Support with Model Master Files
In addition to updates in its technology, EpiVax has filed a new Model Master File (MMF) for its PANDA In Silico Model with the FDA. This filing supports the development of Abbreviated New Drug Applications (ANDA) for generic peptide medications. The PANDA MMF contains detailed methodologies and descriptions of how EpiVax assesses immunogenicity in peptide drugs. This crucial step facilitates a smoother preparation process for ANDA sponsors and provides the FDA with essential validation information regarding the company’s models.
Future Directions and Innovations
EpiVax demonstrates a strong commitment to progress, with future improvements planned for the ISPRI platform. New versions of EpiMatrix are on the horizon, aiming to further expand the toolkit's predictive capabilities. Understanding that user experience is paramount, EpiVax is enhancing the interface of the ISPRI platform, coupled with guided analysis features. This upgraded experience will empower biotechnology firms and pharmaceutical companies to fortify their developmental pipelines, ultimately benefiting patient outcomes through improved therapeutic options.
About EpiVax
EpiVax stands at the forefront of preclinical immunogenicity assessment and sequence optimization. The company offers invaluable services for peptide therapeutics, biologics, and vaccines, intending to accelerate risk assessments. By collaborating with various global entities and academics, EpiVax fosters innovation in immune modulation and rapid vaccine development.
Frequently Asked Questions
Who has been appointed as the new CTO at EpiVax?
Guilhem Richard has been named the Chief Technology Officer at EpiVax, bringing years of experience to the role.
What advancements has EpiVax made in immunoinformatics?
EpiVax has enhanced its ISPRI platform using advanced AI and machine learning, significantly improving risk assessments for biologic therapeutics.
How will the new immunogenicity models affect drug development?
The new models predict anti-drug antibody responses with high accuracy, minimizing false negatives and increasing confidence in assessments.
What is the significance of the PANDA MMF filing?
The PANDA MMF filing supports the regulatory process for ANDA applications, aiding sponsors with comprehensive background on immunogenicity models.
What future developments are expected from EpiVax?
EpiVax plans to release enhanced versions of its ISPRI platform and EpiMatrix, along with a more user-friendly experience overall.
